glp-1 health Comprehensive Nutrition Solutions at Nestlé Science GLP-1 Agonists: Using Semaglutide, Tirzepatide,
Description
Roche's key differentiation strategy is focused on managing side effects
In a 12-week trial involving individuals with a BMI of 2743 kg/m, the highest-dose group achieved an 11.3% average weight reduction, a top-tier result for early-stage trials
But here is what the headlines miss
It is well-tolerated with essentially no side effects, making it an attractive option for patients who prefer non-pharmacological approaches
1 Site-specific analyses showed reduced risks for endometrial (HR 0.75
